ABSTRACT This placebo-controlled, double-blind, longitudinal crossover study compares the efficacy of disopyramide and ethmozine, a new investigational drug, in suppressing frequent (40 or more per hour) ventricular premature depolarizations (VPDs) in 27 patients completing a 37 day protocol. Although both drugs significantly reduced VPDs relative to placebo, ethmozine was a superior antiarrhythmic drug in achieving near-total abolition of VPDs (30% of patients), which was never observed during disopyramide dosing (p < .05). At the 80% VPD reduction level, ethmozine was effective in 56% of all patients compared with an effectiveness in only 22% of patients during disopyramide therapy (p < .05). The mean peak plasma level of ethmozine was 0.66 + 0.8 gg/ml, which significantly fell to a trough level of 0.1 + 0.08 gg/ml (p < .001). Mean peak and trough plasma levels of disopyramide exhibited less fluctuation (2.6 + 0.9 ,ug/ml vs 2.2 0.9 gg/ml). Ethmozine had no effect on the QTC interval, whereas disopyramide prolonged it significantly. Importantly, while disopyramide produced serious side effects in 30% of patients, ethmozine was well tolerated with no statistically significant side effects compared with placebo. Circulation 69, No. 2, 288-297, 1984. EPIDEMIOLOGIC STUDIES in which 12-lead electrocardiograms have been used have documented an increased risk of sudden cardiac death in patients with coronary heart disease who have ventricular premature depolarizations (VPDs). 1-3 Ambulatory electrocardiographic recording has allowed a more systematic and complete quantification of these ventricular arrhythmias that are predictive of sudden cardiac death, especially in patients surviving myocardial infarction.±7
center clinical trials using /3-blockers for patients in the late-hospitalization phase of acute myocardial infarction have shown an overall reduction of sudden cardiac death. I"2 None of these multicenter trials were designed specifically to define the mechanism of this reduction in sudden cardiac death that presumably was a result of preventing sustained ventricular tachycardia and ventricular fibrillation.'3 '4 The classical type I antiarrhythmic drugs (procainamide, quinidine, and disopyramide) are widely used to suppress ventricular rhythm disturbances. While effective in reducing the frequency of VPDs in many patients, all of these drugs have serious side effects. In addition to these undesirable side effects, all three have been documented to cause torsades de pointe ventricular tachycardia. 15-17 A recent report by Velebit et al. 18 documents the frequency with which antiarrhythmic drugs aggravate ventricular rhythm disturbances, with the highest reported frequency caused by quinidine (15.8%).
Disopyramide (Norpace, Searle Pharmaceuticals, Inc.; Chicago) is a recent addition to the type I antiarrhythmic group. Its development as an effective antiar-THERAPY AND PREVENTION-ARRHYTHMIA rhythmic drug to suppress VPDs was documented in a number of clinical trials in the 1970's.9-23 In addition to suppressing VPDs, it was reported to be effective in some cases of drug-resistant ventricular tachycardia. 24 Along with reports of its potential efficacy, there quickly followed a number of reports of frequent side effects and serious toxicity including: atypical ventricular tachycardia and disopyramide-induced ventricular fibrillation", 26; precipitation of left ventricular dysfunction and congestive heart failure27"31; and cardiovascular collapse.32 Nevertheless, since its approval by the Food and Drug Administration in 1978, disopyramide has gained wide acceptance and is used frequently.
Ethmozine (E.L. DuPont de Nemours Company, Wilmington, DE), a phenothiazine derivative, was initially developed in the Soviet Union and was noted to reduce the frequency of ventricular arrhythmias. 3336 Results of investigations in the United States indicate that ethmozine is an effective antiarrhythmic drug for suppressing VPDs with a low incidence of side effects. [37] [38] [39] Few clinical studies are available comparing the effectiveness and toxicity of ethmozine with the effectiveness and toxicity of currently available type I antiarrhythmic drugs.40 Since comparison of efficacy and toxicity are best done with the identical group of patients, this study reports the results of a double-blind longitudinal crossover trial comparing the relative efficacy of disopyramide and ethmozine in reducing VPDs.
Methods
Protocol. This randomized, placebo-controlled, doubleblind, crossover study was performed in 33 patients. The occurrence of .40 VPD/hr on at least two consecutive 24 hr ambulatory electrocardiographic recordings (screening) made up the entry criteria. Of the 33 patients randomized, 27 patients (18 men and nine women, ranging in age from 36 to 72 years) completed the protocol and the data from these patients form the basis of this report. Six patients were dropped from the study. Three of these patients, although having the qualifying arrhythmia during screening (_40 VPD/hr), failed to qualify on placebo monitoring. One patient had chronic heart failure that worsened during placebo and ethmozine dosing and was dropped from the study; invasive evaluation revealed a ventricular septal defect, for which she underwent surgical correction. One patient dropped out during disopyramide dosing due to urinary retention requiring hospitalization, and the sixth dropped out due to poor compliance documented by pill counts.
To qualify for enrollment and randomization, discontinuation of all antiarrhythmic drugs was necessary for 7 days. Previous use of any investigational antiarrhythmic drug was an exclusion criterion. fl-Blockers (five patients) and digitalis (three patients) were not exclusion criteria, but doses were not changed throughout the protocol. Compliance with study medication was monitored by both pill counts and serum levels of the study medications. These 27 patients completed the 37 day protocol. Thirteen patients had ischemic heart disease, 10 with documented myocardial infarction and three with coronary artery disease documented at cardiac catheterization. Of the remaining 14 patients, three had hypertensive heart disease, five had mitral valve prolapse, and one was classified as having idiopathic cardiomyopathy. Five patients were presumably "normal" based on clinical evaluation, exercise testing, and echocardiographic assessment. Fourteen patients had previously received other antiarrhythmic drugs including fl-blockers (six patients), procainamide (five patients), and quinidine (three patients).
Study design. A summary of the protocol design is shown in table 1. The study consisted of an initial 7 day period to receive placebos, followed by 10 day intervals on drug A, the second placebo, and drug B. After a patient demonstrated _40 VPD/hr on two 24 hr ambulatory electrocardiograms, the protocol was explained to the patient and informed consent was obtained. Important design features of this protocol are summarized in table 1 and include: (1) Three days of continuous ambulatory electrocardiographic recording at the end of each treatment period. This allowed 7 days for adequate drug washout and is far in excess of the minimum of five half-lives of the antiarrhythmic drugs being tested. (2) Serum levels of disopyramide and ethmozine were obtained four times on the final 2 days of dosing, with two trough (1 hr before dose) and two peak (1 hr after dose) levels being obtained. (3) Quantitation of VPD rates during the hours that plasma drug samples were obtained, allowing corre- 42 There is a close corre lation between the plasma concentration of disopyramide obtained by this method and those obtained by the Suya EMIP method. The therapeutic range of 2 to 5 ,uggml is the same for both methods. Serum levels of ethmozine were determined by the absorption spectrometric method after high-pressure liquid chromatographic separation. This procedure was described in detail in our previous article.39 Intra-assay and interassay coefficients of variation are 9.7% and 12.1%, respectively, for this method.
Statistical analysis. To ensure complete washout of the active antiarrhythmic drug before the second placebo analysis, the comparability (paired t test) of total VPDs, pairs, and runs of ventricular tachycardia during the first and second placebo periods were compared and analyzed separately for each drug sequence. To test adequacy of randomization, the first placebo periods for sequences A and B were also analyzed for comparability (t test). Also, to eliminate the possibility that either drug sequence altered measured drug effect, the mean percent VPD reduction by each drug was compared in sequences A and B.
Results
Baseline comparability of placebo periods. The comparability of the two placebo dosing periods is demonstrated in table 3 8 .0 ,ug/ml was achieved during ethmozine dosing. One hour before ethmozine dosing, the mean trough serum level had decreased to 0.1 ± 0.08 ,ug/ml (p < .001 vs peak level). Serum levels of disopyramide were less variable with a mean peak serum concentration of 2.6 ± 0.9 gg/ml and a mean trough level of 2.2 ± 0.9 jig/ ml (p > .3, peak vs trough).
Although plasma levels of ethmozine fluctuated significantly, there was no significant difference in the frequency of VPDs during the hours that peak and trough serum levels of ethmozine were obtained (160 ± 283 VPD/hr vs 132 ± 205 VPD/hr, p = NS). Quantitation of VPDs was also performed in all 27 patients during the 2 hr intervals that peak and trough serum levels of disopyramide were obtained. The mean frequency of VPDs was unchanged (300 ± 390 VPD/hr vs 389 ± 452 VPD/hr, p = NS). Correlation coefficients were determined for both samples of peak and trough serum levels of both drugs compared with the VPD rate for the hour the sample was drawn. There was no correlation of peak or trough level to rate of arrhythmia for either ethmozine or disopyramide (all r > .2; p > .5).
Exercise-related ventricular arrhythmias. Of the 27 patients completing the protocol, 16 completed Bruce exercise testing during all four dosing intervals. Of those, 15 patients had VPDs during exercise and/or the recovery phase in their respective placebo periods. During ethmozine dosing four of 15 fects were defined as those of which the patient complained but that would not require discontinuation of the therapy due to unacceptable severity. Severe side effects were those that the patient felt would preclude continuation of the therapy after the 10 day protocol. As seen in table 6, there was no side effect during ethmozine therapy that was significantly greater than during placebo. In contrast, patients experienced a significant increase in both urinary complaints and dry mouths during disopyramide therapy. Eight of the 27 patients reported that side effects during the disopyramide dosing phase were unacceptable (dry mouth and urinary symptoms), and they would not continue that drug. Additionally, one patient was dropped from the study when he developed urinary retention during disopyramide therapy.
Discussion
Study design. A double-blind longitudinal crossover design has the advantage of comparing two antiarrhythmic drugs in the same patient population, rather than in two different patient populations as in a parallel-design protocol. The 10 day intervals between crossover of active antiarrhythmic drugs was far in excess of five drug half-lives of both ethmozine37l-9 and disopyramide,20 both of which have half-lives less than 6 hr. We demonstrated "physiologic washout" of each antiarrhythmic drug by the return to baseline of the arrhythmia frequency during the second placebo period. Thus, we established the comparability of the first and second placebo periods in both drug sequences, that is, regardless of whether ethmozine or disopyramide was the first active antiarrhythmic drug given. We also confirmed that randomization of patients in drug sequences A and B produced comparable arrhythmia frequency and variability. Thus, based on this analysis, both successful randomization and the adequacy of drug washout during the second placebo period allowed meaningful comparison of these two antiarrhythmic drugs in this patient population defined by a high frequency of VPDs.
The dosage range chosen for each of these antiarrhythmic drugs was in the moderate range. The majority of published studies reporting the antiarrhythmic efficacy of disopyramide have used an average dose of 150 mg four times daily,20 23 although some have used lower doses of 100 mg four times daily.24 Although a higher dose of disopyramide could have been chosen for this study, the dose chosen led to unacceptable side effects in 30% of patients that may have increased further had a higher dose range been chosen.
The ethmozine dose of 10 mg/kg/day (divided three times a day) was selected on the basis of our own recent experience.39 Ethmozine is currently being administered in doses of up to 14 mg/kg/day in some clinical trials. Since the dose chosen for this protocol did not lead to significant side effects in any of the patients, it would be of interest to assess a higher dose. However, it was our experience that patients failing to respond to the 10 mg/kg/day dosage usually did not receive further benefit from higher doses. 39 Three days of 24 hr ambulatory electrocardiographic recordings were chosen to establish VPD frequency during placebo as well as VPD frequency during treatment in both treatment sequences; this was based on the well-documented variability of single and complex ventricular arrhythmias on sequential 24 hr ambulatory electrocardiographic recordings.43A5 Based on 3 days of ambulatory electrocardiographic quantitation of VPDs in patients on placebos and drugs, Morganroth et al. 4 have established a 64.6% minimal VPD reduction rate to establish drug efficacy in individual patients. Using a mixed-model analysis of variance on 24 hr VPD frequencies, Sami et al. 46 have concluded that the minimal percent reduction required to establish drug efficacy at a 95% one-tail confidence level may be somewhat lower than that reported by Morganroth et al. Regardless of which criteria are used for determining efficacy, the duration of ambulatory electrocardiographic recording in this study compares favorably with most drug trials and in fact exceeds that of most published data. 47 Antiarrhythmic efficacy of disopyramide vs ethmozine.
Both disopyramide and ethmozine were effective in reducing the mean frequency of VPDs. For the entire group of 27 patients, a 52.8% reduction in total VPDs documented during disopyramide therapy is somewhat lower than that of other published studies, many using intravenous disopyramide with efficacy documented with only electrocardiographic rhythm strips'9 21 patients. Furthermore, severe cases of toxicity, including cardiovascular collapse, have been reported at plasma concentrations of disopyramide of 4.9 to 8.1 ng/ml.32 There was no significant change between peak and trough plasma levels of disopyramide in this study. Also, there was no demonstrable change in relative reduction of arrhythmia during monitoring periods of peak and trough levels (r < .2).
Plasma levels of ethmozine fluctuated significantly, reaching peak mean levels of 0.66 + 0.8 ng/ml, a slightly higher mean plasma level of ethmozine than we previously reported in our 39 patients with an average dose of 10.1 mg/kg/day (0.42 ± 0.28 ng/ml).39 Despite low plasma trough levels (0.1 ± 0.08 ng/ml, p < .001), there was no significant change in the degree of VPD reduction. Drug effect did not appear to correlate with plasma level of ethmozine, a fact consistent with our previously reported data.39
Electrocardiographic, laboratory, and echocardiographic assessment. Disopyramide significantly increased PR duration and QTC duration, with a trend to increased QRS duration. These alterations of the standard 12-lead electrocardiogram are consistent with previously reported studies. 19-24 While ethmozine significantly increased both PR and QRS duration, it had no effect on QTc duration. These findings were also consistent with previously reported electrocardiographic changes. There were no significant changes in routine laboratory parameters with either antiarrhythmic drug. Although there were no demonstrable changes in global left ventricular ejection fraction calculated from the two-dimensional echocardiogram,4' the trend to decreased left ventricular function on disopyramide therapy in patients with global left ventricular ejection fractions less than 40% is consistent with previously reported studies of reduced left ventricular function during disopyramide therapy.3'32 However, no patient developed overt congestive heart failure during disopyramide dosing. There were no changes in left ventricular function as measured by two-dimensional echocardiography during ethmozine dosing. However, one patient was dropped from the study when she developed congestive heart failure while on ethmozine therapy. This patient had a deteriorating clinical situation during the previous placebo period and was not responding to digitalization and diuretics; she was subsequently found to have a significant ventricular septal defect requiring surgery. It was not our opinion that this deterioration was due to ethmozine.
Assessment of side effects of drugs. The study design allowed assessment of side effects and toxicity of each antiarrhythmic drug compared with its respective pla-cebo period. The previous reports of side effects with disopyramide2'>24 were confirmed by this study. At moderate doses of disopyramide (150 mg every 6 hr) achieving a mean peak plasma concentration of 2.6 ,ug/ml, 30% of the patients reported intolerable side effects (either dry mouth and/or urinary symptoms) of sufficient magnitude that they would not consider continuing the medication on a long-term basis. Peak serum levels of disopyramide were not significantly different in patients who did or did not experience dry mouth (2.27+ 0.98,g vs 2.79 ± 0.83 gg; p -NS).
Likewise, peak serum levels of disopyramide were not significantly different in patients with or without urinary symptoms (2.65 ± 0.62,g vs2.55 ± 0.93,g; p = NS). The frequency of these side effects reached statistical significance compared with those of both placebo and ethmozine therapy. Patients on ethmozine were remarkably free of side effects, with none of the effects approaching statistical significance compared with those of patients on placebo. This is consistent with previous published data reporting this drug to have a low incidence of minor side effects with no serious toxicity. Conclusion. Relative to placebo, both disopyramide and ethmozine significantly reduced total VPDs in this study. However, ethmozine was a superior antiarrhythmic drug, with near total VPD suppression in 30% of all patients, which was not observed in any patient on disopyramide. Both drugs were effective in suppressing nonsustained ventricular tachycardia. Importantly, ethmozine does not prolong the QTC interval. In contrast to disopyramide, ethmozine was not only a more effective antiarrhythmic drug but was also well tolerated with no significant side effects, meriting further consideration for long-term clinical studies to define its role relative to other new promising antiarrhythmic drugs.
